| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Neoplasms | 63 | 2024 | 1425 | 11.330 |
Why?
|
| Endometrial Neoplasms | 78 | 2023 | 1378 | 9.430 |
Why?
|
| Endometrial Stromal Tumors | 18 | 2023 | 46 | 7.660 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 26 | 2024 | 117 | 6.770 |
Why?
|
| Sarcoma, Endometrial Stromal | 25 | 2023 | 92 | 6.470 |
Why?
|
| Carcinoma, Endometrioid | 33 | 2023 | 274 | 5.990 |
Why?
|
| Ovarian Neoplasms | 80 | 2024 | 4904 | 5.440 |
Why?
|
| Uterine Cervical Neoplasms | 46 | 2024 | 2040 | 4.760 |
Why?
|
| Genital Neoplasms, Female | 16 | 2022 | 534 | 4.010 |
Why?
|
| Immunohistochemistry | 100 | 2024 | 11030 | 3.140 |
Why?
|
| Smooth Muscle Tumor | 12 | 2021 | 64 | 3.050 |
Why?
|
| Perivascular Epithelioid Cell Neoplasms | 7 | 2023 | 78 | 2.750 |
Why?
|
| Carcinoma | 24 | 2022 | 2311 | 2.460 |
Why?
|
| Leiomyoma | 12 | 2024 | 644 | 2.400 |
Why?
|
| Adenocarcinoma | 39 | 2024 | 6360 | 2.340 |
Why?
|
| Adenocarcinoma, Clear Cell | 15 | 2022 | 217 | 2.180 |
Why?
|
| Leiomyosarcoma | 16 | 2023 | 425 | 2.170 |
Why?
|
| In Situ Hybridization, Fluorescence | 29 | 2024 | 2510 | 2.030 |
Why?
|
| Diagnosis, Differential | 75 | 2024 | 12973 | 2.010 |
Why?
|
| Adenosarcoma | 5 | 2022 | 36 | 1.950 |
Why?
|
| Pathology | 8 | 2024 | 270 | 1.950 |
Why?
|
| Gynecology | 18 | 2024 | 534 | 1.800 |
Why?
|
| Carcinosarcoma | 9 | 2019 | 106 | 1.750 |
Why?
|
| Uterus | 15 | 2023 | 660 | 1.660 |
Why?
|
| Vulvar Neoplasms | 8 | 2022 | 265 | 1.600 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 3 | 2022 | 97 | 1.520 |
Why?
|
| Gene Rearrangement | 16 | 2020 | 1143 | 1.480 |
Why?
|
| Female | 336 | 2024 | 396141 | 1.460 |
Why?
|
| Neoplasm Staging | 57 | 2024 | 11196 | 1.440 |
Why?
|
| Papillomavirus Infections | 18 | 2024 | 1637 | 1.360 |
Why?
|
| Gene Fusion | 12 | 2022 | 357 | 1.360 |
Why?
|
| Endometrium | 12 | 2023 | 404 | 1.330 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 10 | 2024 | 702 | 1.320 |
Why?
|
| 14-3-3 Proteins | 6 | 2023 | 221 | 1.300 |
Why?
|
| Myofibroma | 2 | 2020 | 45 | 1.260 |
Why?
|
| Myelodysplastic Syndromes | 12 | 2023 | 1404 | 1.250 |
Why?
|
| Cystadenocarcinoma, Serous | 11 | 2022 | 480 | 1.240 |
Why?
|
| Hysterectomy | 15 | 2022 | 864 | 1.240 |
Why?
|
| Adenocarcinoma, Mucinous | 6 | 2020 | 521 | 1.230 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 5 | 2018 | 388 | 1.190 |
Why?
|
| DNA Mismatch Repair | 5 | 2022 | 432 | 1.120 |
Why?
|
| Testicular Neoplasms | 8 | 2024 | 800 | 1.100 |
Why?
|
| Ribonuclease III | 5 | 2022 | 271 | 1.090 |
Why?
|
| Peutz-Jeghers Syndrome | 2 | 2024 | 61 | 1.090 |
Why?
|
| Adnexal Diseases | 3 | 2019 | 104 | 1.070 |
Why?
|
| Humans | 363 | 2024 | 765926 | 1.040 |
Why?
|
| Azacitidine | 4 | 2024 | 334 | 1.040 |
Why?
|
| Cysts | 4 | 2024 | 684 | 1.010 |
Why?
|
| DEAD-box RNA Helicases | 5 | 2022 | 386 | 1.010 |
Why?
|
| Carcinoma, Small Cell | 6 | 2022 | 420 | 1.000 |
Why?
|
| Papillomaviridae | 15 | 2023 | 1137 | 1.000 |
Why?
|
| Granulosa Cell Tumor | 9 | 2024 | 76 | 1.000 |
Why?
|
| Carcinoma, Adenosquamous | 4 | 2022 | 66 | 0.990 |
Why?
|
| Chromosomes, Human, Pair 5 | 3 | 2018 | 386 | 0.960 |
Why?
|
| MutS Homolog 2 Protein | 4 | 2019 | 200 | 0.950 |
Why?
|
| Middle Aged | 173 | 2024 | 223016 | 0.920 |
Why?
|
| DNA-Binding Proteins | 25 | 2024 | 9600 | 0.920 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 4 | 2021 | 323 | 0.910 |
Why?
|
| Pregnancy Complications, Neoplastic | 6 | 2020 | 258 | 0.910 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 2 | 2022 | 26 | 0.900 |
Why?
|
| Adenoma | 5 | 2022 | 2155 | 0.900 |
Why?
|
| Prognosis | 59 | 2024 | 29890 | 0.890 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 6 | 2022 | 483 | 0.880 |
Why?
|
| Neoplasm Proteins | 18 | 2021 | 3592 | 0.850 |
Why?
|
| Mixed Tumor, Mullerian | 6 | 2017 | 55 | 0.850 |
Why?
|
| Broad Ligament | 1 | 2022 | 4 | 0.810 |
Why?
|
| Genitalia, Female | 3 | 2020 | 146 | 0.800 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 1 | 2022 | 30 | 0.800 |
Why?
|
| Adult | 152 | 2024 | 223088 | 0.800 |
Why?
|
| Aged | 138 | 2024 | 171163 | 0.800 |
Why?
|
| Teratoma | 4 | 2022 | 402 | 0.790 |
Why?
|
| Cervix Uteri | 12 | 2024 | 575 | 0.780 |
Why?
|
| Neoplasms, Muscle Tissue | 2 | 2024 | 68 | 0.780 |
Why?
|
| Chromosome Deletion | 3 | 2018 | 1384 | 0.760 |
Why?
|
| Choristoma | 1 | 2023 | 205 | 0.760 |
Why?
|
| Transcription Factors | 20 | 2021 | 12129 | 0.750 |
Why?
|
| Carcinoma, Transitional Cell | 10 | 2024 | 789 | 0.750 |
Why?
|
| Adenomatoid Tumor | 1 | 2021 | 12 | 0.740 |
Why?
|
| Carcinoma, Squamous Cell | 12 | 2024 | 4044 | 0.740 |
Why?
|
| Hypercalcemia | 6 | 2019 | 425 | 0.730 |
Why?
|
| Solitary Fibrous Tumors | 1 | 2022 | 70 | 0.730 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2020 | 40 | 0.720 |
Why?
|
| Thalidomide | 3 | 2016 | 886 | 0.720 |
Why?
|
| Germinoma | 4 | 2022 | 124 | 0.690 |
Why?
|
| Sarcoma | 9 | 2023 | 1799 | 0.680 |
Why?
|
| Neoplasm Invasiveness | 25 | 2024 | 3599 | 0.680 |
Why?
|
| Adnexa Uteri | 1 | 2019 | 40 | 0.670 |
Why?
|
| Androgen-Insensitivity Syndrome | 2 | 2018 | 33 | 0.670 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2022 | 249 | 0.670 |
Why?
|
| Kidney Neoplasms | 10 | 2024 | 4278 | 0.670 |
Why?
|
| Remission Induction | 2 | 2024 | 2413 | 0.630 |
Why?
|
| Societies, Medical | 17 | 2021 | 3953 | 0.630 |
Why?
|
| Necrosis | 8 | 2022 | 1611 | 0.630 |
Why?
|
| Co-Repressor Proteins | 6 | 2023 | 189 | 0.630 |
Why?
|
| Precancerous Conditions | 6 | 2021 | 975 | 0.630 |
Why?
|
| Isochromosomes | 1 | 2018 | 16 | 0.630 |
Why?
|
| Aged, 80 and over | 69 | 2024 | 59496 | 0.620 |
Why?
|
| Fumarate Hydratase | 2 | 2024 | 55 | 0.610 |
Why?
|
| Ovarian Diseases | 3 | 2015 | 133 | 0.610 |
Why?
|
| Placenta | 4 | 2020 | 1726 | 0.610 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 340 | 0.610 |
Why?
|
| Epithelioid Cells | 1 | 2018 | 61 | 0.610 |
Why?
|
| Neprilysin | 6 | 2007 | 484 | 0.600 |
Why?
|
| Genital Diseases, Female | 3 | 2015 | 192 | 0.600 |
Why?
|
| Carcinoma, Papillary | 4 | 2015 | 786 | 0.600 |
Why?
|
| Tissue Array Analysis | 13 | 2021 | 544 | 0.590 |
Why?
|
| Nuclear Proteins | 10 | 2021 | 5782 | 0.590 |
Why?
|
| DNA Repair Enzymes | 2 | 2018 | 342 | 0.590 |
Why?
|
| Mutation | 29 | 2024 | 30192 | 0.580 |
Why?
|
| Fibronectins | 1 | 2021 | 720 | 0.580 |
Why?
|
| beta Catenin | 10 | 2023 | 1046 | 0.570 |
Why?
|
| Tumor Suppressor Protein p53 | 13 | 2023 | 2945 | 0.570 |
Why?
|
| Mesothelioma | 2 | 2022 | 774 | 0.570 |
Why?
|
| Neoplasms, Glandular and Epithelial | 3 | 2013 | 488 | 0.570 |
Why?
|
| Urethral Neoplasms | 6 | 2010 | 37 | 0.560 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2019 | 154 | 0.560 |
Why?
|
| Pancreas | 2 | 2023 | 1698 | 0.560 |
Why?
|
| Molecular Diagnostic Techniques | 2 | 2019 | 614 | 0.560 |
Why?
|
| Urinary Bladder Neoplasms | 10 | 2014 | 2176 | 0.560 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2017 | 43 | 0.560 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2018 | 432 | 0.550 |
Why?
|
| Proto-Oncogene Proteins | 6 | 2021 | 4520 | 0.550 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 6 | 2020 | 194 | 0.550 |
Why?
|
| Peritoneal Neoplasms | 2 | 2022 | 706 | 0.540 |
Why?
|
| Carcinoma, Renal Cell | 6 | 2021 | 3183 | 0.520 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 655 | 0.510 |
Why?
|
| Predictive Value of Tests | 28 | 2024 | 15401 | 0.510 |
Why?
|
| Carcinoma in Situ | 5 | 2021 | 777 | 0.500 |
Why?
|
| WT1 Proteins | 3 | 2015 | 182 | 0.500 |
Why?
|
| Fallopian Tube Neoplasms | 6 | 2015 | 329 | 0.490 |
Why?
|
| Giant Cell Tumors | 1 | 2015 | 89 | 0.490 |
Why?
|
| Repressor Proteins | 7 | 2023 | 2969 | 0.480 |
Why?
|
| Cell Nucleus Shape | 1 | 2014 | 16 | 0.480 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2024 | 6503 | 0.480 |
Why?
|
| Osteosarcoma | 2 | 2018 | 908 | 0.480 |
Why?
|
| Myometrium | 6 | 2021 | 174 | 0.470 |
Why?
|
| Lymph Nodes | 10 | 2022 | 3447 | 0.470 |
Why?
|
| Practice Guidelines as Topic | 15 | 2021 | 7423 | 0.460 |
Why?
|
| Stromal Cells | 10 | 2020 | 1332 | 0.460 |
Why?
|
| Lymphatic Metastasis | 12 | 2024 | 2885 | 0.460 |
Why?
|
| Cyclin D1 | 7 | 2023 | 449 | 0.450 |
Why?
|
| Muscle, Smooth | 4 | 2014 | 931 | 0.450 |
Why?
|
| Oncogene Proteins, Fusion | 7 | 2023 | 1609 | 0.450 |
Why?
|
| Adenosine Triphosphatases | 3 | 2016 | 839 | 0.440 |
Why?
|
| Leukemia, Myeloid | 3 | 2011 | 695 | 0.440 |
Why?
|
| Leukemia, Myeloid, Acute | 7 | 2024 | 3637 | 0.440 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2013 | 723 | 0.440 |
Why?
|
| Neoplasm Recurrence, Local | 18 | 2024 | 9373 | 0.440 |
Why?
|
| Ovary | 7 | 2021 | 961 | 0.430 |
Why?
|
| Biopsy | 14 | 2022 | 6766 | 0.430 |
Why?
|
| DNA Helicases | 4 | 2021 | 852 | 0.420 |
Why?
|
| Angiomyolipoma | 2 | 2013 | 189 | 0.420 |
Why?
|
| DNA Mutational Analysis | 15 | 2022 | 4111 | 0.420 |
Why?
|
| Mitosis | 5 | 2023 | 1175 | 0.410 |
Why?
|
| Infertility, Female | 1 | 2018 | 763 | 0.400 |
Why?
|
| Lipoma | 2 | 2011 | 294 | 0.400 |
Why?
|
| Receptors, Progesterone | 6 | 2019 | 1152 | 0.390 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 2423 | 0.390 |
Why?
|
| Neoplasms, Connective and Soft Tissue | 2 | 2023 | 34 | 0.390 |
Why?
|
| Mitotic Index | 6 | 2020 | 160 | 0.390 |
Why?
|
| Endometrial Hyperplasia | 3 | 2021 | 101 | 0.380 |
Why?
|
| Uterine Hemorrhage | 1 | 2013 | 235 | 0.380 |
Why?
|
| DNA, Neoplasm | 7 | 2018 | 1739 | 0.360 |
Why?
|
| Forkhead Transcription Factors | 2 | 2015 | 1623 | 0.360 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2024 | 645 | 0.360 |
Why?
|
| Survival Rate | 22 | 2021 | 12822 | 0.360 |
Why?
|
| Cell Nucleus | 9 | 2023 | 2864 | 0.360 |
Why?
|
| HMGA2 Protein | 2 | 2012 | 101 | 0.360 |
Why?
|
| Anti-Mullerian Hormone | 5 | 2023 | 420 | 0.360 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2010 | 89 | 0.360 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2013 | 2046 | 0.360 |
Why?
|
| Premenopause | 1 | 2015 | 1039 | 0.360 |
Why?
|
| Observer Variation | 12 | 2021 | 2611 | 0.350 |
Why?
|
| Vaginal Neoplasms | 3 | 2012 | 105 | 0.350 |
Why?
|
| Soft Tissue Neoplasms | 3 | 2023 | 1163 | 0.340 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2010 | 95 | 0.340 |
Why?
|
| Mullerian Ducts | 3 | 2019 | 203 | 0.340 |
Why?
|
| Iron Overload | 3 | 2017 | 245 | 0.340 |
Why?
|
| Erythropoietin | 4 | 2018 | 716 | 0.340 |
Why?
|
| Choriocarcinoma | 2 | 2004 | 121 | 0.330 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2011 | 589 | 0.330 |
Why?
|
| Immunologic Factors | 2 | 2016 | 1590 | 0.330 |
Why?
|
| Wolffian Ducts | 2 | 2022 | 27 | 0.330 |
Why?
|
| Stomach Neoplasms | 4 | 2022 | 1469 | 0.310 |
Why?
|
| Leiomyomatosis | 4 | 2020 | 69 | 0.310 |
Why?
|
| Chromosome Aberrations | 3 | 2024 | 1775 | 0.310 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2012 | 540 | 0.310 |
Why?
|
| Disease-Free Survival | 9 | 2024 | 6838 | 0.300 |
Why?
|
| Alphapapillomavirus | 2 | 2022 | 219 | 0.300 |
Why?
|
| Endometriosis | 4 | 2015 | 869 | 0.300 |
Why?
|
| Liposarcoma | 1 | 2011 | 288 | 0.300 |
Why?
|
| Boston | 9 | 2021 | 9334 | 0.290 |
Why?
|
| Cystadenocarcinoma, Papillary | 2 | 2006 | 56 | 0.290 |
Why?
|
| Frozen Sections | 1 | 2008 | 152 | 0.290 |
Why?
|
| Rhabdoid Tumor | 2 | 2020 | 209 | 0.290 |
Why?
|
| Tumor Burden | 7 | 2024 | 1888 | 0.290 |
Why?
|
| Nephroma, Mesoblastic | 1 | 2007 | 25 | 0.280 |
Why?
|
| Cell Transformation, Neoplastic | 10 | 2020 | 2838 | 0.280 |
Why?
|
| Young Adult | 28 | 2024 | 59857 | 0.270 |
Why?
|
| Tuberous Sclerosis | 2 | 2014 | 1039 | 0.270 |
Why?
|
| Keratins | 6 | 2010 | 497 | 0.270 |
Why?
|
| Retrospective Studies | 45 | 2024 | 81537 | 0.270 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 2897 | 0.270 |
Why?
|
| Neoplasms, Second Primary | 2 | 2012 | 1056 | 0.260 |
Why?
|
| Nephrectomy | 3 | 2021 | 927 | 0.260 |
Why?
|
| Lymph Node Excision | 7 | 2023 | 1258 | 0.260 |
Why?
|
| Cyclins | 3 | 2007 | 598 | 0.260 |
Why?
|
| Myxoma | 1 | 2006 | 114 | 0.250 |
Why?
|
| Combined Modality Therapy | 14 | 2017 | 8522 | 0.250 |
Why?
|
| Postmenopause | 1 | 2015 | 2517 | 0.250 |
Why?
|
| Anemia | 2 | 2018 | 1514 | 0.250 |
Why?
|
| Receptors, Transforming Growth Factor beta | 4 | 2023 | 305 | 0.250 |
Why?
|
| Urologic Neoplasms | 2 | 2006 | 312 | 0.250 |
Why?
|
| Adolescent | 34 | 2024 | 88811 | 0.250 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2019 | 86 | 0.250 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 2559 | 0.250 |
Why?
|
| Fatal Outcome | 4 | 2018 | 1835 | 0.240 |
Why?
|
| Telomerase | 2 | 2022 | 749 | 0.240 |
Why?
|
| Sertoli Cell Tumor | 1 | 2005 | 35 | 0.240 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2013 | 2877 | 0.230 |
Why?
|
| Fallopian Tubes | 3 | 2011 | 179 | 0.230 |
Why?
|
| Human papillomavirus 18 | 2 | 2022 | 125 | 0.230 |
Why?
|
| Calmodulin-Binding Proteins | 3 | 2017 | 237 | 0.230 |
Why?
|
| Terminology as Topic | 5 | 2018 | 1536 | 0.230 |
Why?
|
| Endodermal Sinus Tumor | 2 | 2022 | 53 | 0.220 |
Why?
|
| Perinatal Care | 1 | 2006 | 243 | 0.220 |
Why?
|
| Follow-Up Studies | 16 | 2022 | 39228 | 0.220 |
Why?
|
| Hematinics | 3 | 2018 | 282 | 0.220 |
Why?
|
| Kidney Pelvis | 1 | 2024 | 191 | 0.210 |
Why?
|
| Gonadoblastoma | 2 | 2022 | 14 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 12 | 2020 | 8603 | 0.210 |
Why?
|
| Colonic Neoplasms | 3 | 2018 | 2530 | 0.210 |
Why?
|
| Human papillomavirus 16 | 2 | 2022 | 268 | 0.210 |
Why?
|
| Education, Distance | 2 | 2024 | 260 | 0.210 |
Why?
|
| Translocation, Genetic | 4 | 2011 | 1393 | 0.210 |
Why?
|
| Ovariectomy | 3 | 2017 | 612 | 0.210 |
Why?
|
| Retroperitoneal Space | 1 | 2023 | 175 | 0.210 |
Why?
|
| Papilloma | 1 | 2023 | 141 | 0.200 |
Why?
|
| Treatment Outcome | 22 | 2024 | 65194 | 0.200 |
Why?
|
| Cadherins | 4 | 2016 | 899 | 0.200 |
Why?
|
| Peptide Hormones | 1 | 2023 | 133 | 0.200 |
Why?
|
| Abdominal Neoplasms | 2 | 2019 | 285 | 0.200 |
Why?
|
| Receptors, Peptide | 3 | 2021 | 280 | 0.200 |
Why?
|
| Dioxygenases | 1 | 2024 | 354 | 0.200 |
Why?
|
| Urothelium | 3 | 2024 | 275 | 0.200 |
Why?
|
| Orchiectomy | 2 | 2022 | 465 | 0.200 |
Why?
|
| Male | 63 | 2024 | 363815 | 0.190 |
Why?
|
| Germ-Line Mutation | 3 | 2023 | 1885 | 0.190 |
Why?
|
| Pyrroles | 1 | 2008 | 1119 | 0.190 |
Why?
|
| Metaplasia | 3 | 2014 | 325 | 0.190 |
Why?
|
| Receptor, trkA | 2 | 2023 | 159 | 0.190 |
Why?
|
| Gastric Mucosa | 2 | 2023 | 602 | 0.190 |
Why?
|
| Glomus Tumor | 1 | 2022 | 62 | 0.190 |
Why?
|
| Mesenchymoma | 2 | 2007 | 50 | 0.190 |
Why?
|
| Serous Membrane | 1 | 2021 | 22 | 0.190 |
Why?
|
| Immunophenotyping | 4 | 2021 | 1865 | 0.190 |
Why?
|
| Phenotype | 10 | 2023 | 16714 | 0.190 |
Why?
|
| Histone Deacetylases | 1 | 2006 | 714 | 0.190 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 13446 | 0.190 |
Why?
|
| Claudins | 1 | 2022 | 118 | 0.190 |
Why?
|
| Quality of Life | 5 | 2019 | 13463 | 0.180 |
Why?
|
| Curettage | 1 | 2021 | 74 | 0.180 |
Why?
|
| Carrier Proteins | 5 | 2011 | 4909 | 0.180 |
Why?
|
| Iron Chelating Agents | 3 | 2017 | 141 | 0.180 |
Why?
|
| In Situ Hybridization | 4 | 2018 | 1885 | 0.180 |
Why?
|
| Genes, cdc | 1 | 2020 | 113 | 0.180 |
Why?
|
| Oncogene Fusion | 1 | 2020 | 84 | 0.180 |
Why?
|
| Testicular Diseases | 1 | 2000 | 72 | 0.170 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2021 | 158 | 0.170 |
Why?
|
| Racemases and Epimerases | 4 | 2022 | 113 | 0.170 |
Why?
|
| Chromosomal Proteins, Non-Histone | 3 | 2015 | 723 | 0.170 |
Why?
|
| Sarcoma, Alveolar Soft Part | 2 | 2017 | 44 | 0.170 |
Why?
|
| Neoplasm Metastasis | 6 | 2018 | 4882 | 0.170 |
Why?
|
| Inhibins | 4 | 2021 | 210 | 0.170 |
Why?
|
| Respiratory Mucosa | 1 | 2023 | 437 | 0.170 |
Why?
|
| Sarcoma, Synovial | 2 | 2019 | 157 | 0.170 |
Why?
|
| Indoles | 1 | 2008 | 1833 | 0.170 |
Why?
|
| Proportional Hazards Models | 6 | 2015 | 12529 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 8 | 2017 | 6058 | 0.170 |
Why?
|
| Time Factors | 10 | 2024 | 40097 | 0.170 |
Why?
|
| Benzoates | 1 | 2021 | 213 | 0.170 |
Why?
|
| Muscle Neoplasms | 2 | 2011 | 130 | 0.170 |
Why?
|
| RNA-Binding Proteins | 3 | 2017 | 1882 | 0.170 |
Why?
|
| Hydrazines | 1 | 2021 | 223 | 0.170 |
Why?
|
| Pelvic Floor | 2 | 2011 | 138 | 0.170 |
Why?
|
| Keratin-20 | 2 | 2012 | 31 | 0.170 |
Why?
|
| Phosphoproteins | 3 | 2007 | 2444 | 0.160 |
Why?
|
| Reproducibility of Results | 14 | 2023 | 20133 | 0.160 |
Why?
|
| Thrombopoietin | 1 | 2021 | 225 | 0.160 |
Why?
|
| Cicatrix | 1 | 2005 | 796 | 0.160 |
Why?
|
| Cell Differentiation | 7 | 2021 | 11639 | 0.160 |
Why?
|
| Chelation Therapy | 2 | 2017 | 76 | 0.160 |
Why?
|
| Abdomen | 1 | 2005 | 1135 | 0.160 |
Why?
|
| Pelvic Neoplasms | 2 | 2011 | 248 | 0.160 |
Why?
|
| Receptors, Estrogen | 5 | 2018 | 2242 | 0.160 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2022 | 455 | 0.160 |
Why?
|
| Loss of Heterozygosity | 3 | 2011 | 663 | 0.160 |
Why?
|
| Hepatocytes | 2 | 2017 | 1247 | 0.160 |
Why?
|
| Myofibroblasts | 1 | 2020 | 230 | 0.150 |
Why?
|
| GATA3 Transcription Factor | 2 | 2018 | 163 | 0.150 |
Why?
|
| Receptors, Steroid | 1 | 2019 | 155 | 0.150 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2019 | 202 | 0.150 |
Why?
|
| 46, XX Disorders of Sex Development | 1 | 2018 | 34 | 0.150 |
Why?
|
| Receptor, trkC | 1 | 2018 | 63 | 0.150 |
Why?
|
| Mentors | 1 | 2024 | 671 | 0.150 |
Why?
|
| Gene Dosage | 2 | 2020 | 1213 | 0.150 |
Why?
|
| Pregnancy | 9 | 2020 | 30230 | 0.150 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2017 | 2325 | 0.150 |
Why?
|
| Iron | 2 | 2017 | 1811 | 0.150 |
Why?
|
| Adenofibroma | 2 | 2008 | 25 | 0.150 |
Why?
|
| Epoetin Alfa | 1 | 2018 | 78 | 0.150 |
Why?
|
| Child | 17 | 2024 | 80568 | 0.150 |
Why?
|
| Receptors, Fc | 1 | 2021 | 537 | 0.150 |
Why?
|
| Research Report | 1 | 2021 | 367 | 0.140 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 2 | 2015 | 93 | 0.140 |
Why?
|
| DNA Polymerase II | 1 | 2018 | 103 | 0.140 |
Why?
|
| Rh Isoimmunization | 1 | 2017 | 23 | 0.140 |
Why?
|
| Vulva | 1 | 2018 | 84 | 0.140 |
Why?
|
| Salpingectomy | 1 | 2017 | 45 | 0.140 |
Why?
|
| Pathology, Surgical | 2 | 2010 | 146 | 0.140 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2021 | 245 | 0.140 |
Why?
|
| Electron Transport Complex I | 1 | 2018 | 150 | 0.140 |
Why?
|
| North America | 4 | 2024 | 1287 | 0.140 |
Why?
|
| DNA, Viral | 3 | 2015 | 2196 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2021 | 730 | 0.140 |
Why?
|
| British Columbia | 2 | 2021 | 238 | 0.140 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2018 | 150 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2015 | 4563 | 0.130 |
Why?
|
| Europe | 6 | 2024 | 3430 | 0.130 |
Why?
|
| Melanoma | 3 | 2020 | 5695 | 0.130 |
Why?
|
| Fibrosarcoma | 1 | 2018 | 312 | 0.130 |
Why?
|
| Demography | 1 | 2021 | 1640 | 0.130 |
Why?
|
| Keratin-7 | 2 | 2006 | 55 | 0.130 |
Why?
|
| Oncogenes | 2 | 2012 | 1232 | 0.130 |
Why?
|
| Cell Nucleolus | 2 | 2015 | 156 | 0.130 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2017 | 211 | 0.130 |
Why?
|
| TNF Receptor-Associated Factor 6 | 2 | 2013 | 59 | 0.130 |
Why?
|
| Calpain | 1 | 2016 | 146 | 0.130 |
Why?
|
| Glutathione | 1 | 2018 | 588 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2019 | 11858 | 0.120 |
Why?
|
| Liver Neoplasms | 3 | 2017 | 4349 | 0.120 |
Why?
|
| History, 20th Century | 2 | 2014 | 2760 | 0.120 |
Why?
|
| Hemoglobinopathies | 1 | 2016 | 101 | 0.120 |
Why?
|
| Krukenberg Tumor | 1 | 2015 | 12 | 0.120 |
Why?
|
| Hong Kong | 1 | 2015 | 169 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 580 | 0.120 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 2141 | 0.120 |
Why?
|
| Gene Amplification | 3 | 2015 | 1088 | 0.120 |
Why?
|
| Ploidies | 4 | 2019 | 287 | 0.120 |
Why?
|
| Apoptosis | 5 | 2016 | 9505 | 0.120 |
Why?
|
| Pathology, Clinical | 1 | 2019 | 374 | 0.120 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2016 | 181 | 0.120 |
Why?
|
| Uterine Cervical Diseases | 1 | 1995 | 75 | 0.120 |
Why?
|
| Neuroectodermal Tumors | 1 | 1994 | 23 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2021 | 18074 | 0.120 |
Why?
|
| Lymphoma | 3 | 2020 | 1896 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2024 | 3661 | 0.120 |
Why?
|
| Annexin A2 | 1 | 2014 | 43 | 0.120 |
Why?
|
| Polycythemia | 1 | 2015 | 124 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2017 | 958 | 0.120 |
Why?
|
| Fibroma | 2 | 2015 | 197 | 0.110 |
Why?
|
| Ureteral Neoplasms | 1 | 1995 | 106 | 0.110 |
Why?
|
| Paclitaxel | 5 | 2006 | 1726 | 0.110 |
Why?
|
| Muscle Proteins | 1 | 2020 | 1160 | 0.110 |
Why?
|
| Hyalin | 1 | 2014 | 35 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2008 | 2970 | 0.110 |
Why?
|
| Endometritis | 1 | 2014 | 49 | 0.110 |
Why?
|
| Brachytherapy | 1 | 2022 | 1218 | 0.110 |
Why?
|
| Blood Transfusion | 3 | 2018 | 1307 | 0.110 |
Why?
|
| Liver | 3 | 2017 | 7559 | 0.110 |
Why?
|
| Monitoring, Immunologic | 1 | 2014 | 99 | 0.110 |
Why?
|
| Urethra | 2 | 2010 | 406 | 0.110 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2015 | 308 | 0.110 |
Why?
|
| Infarction | 2 | 2013 | 247 | 0.110 |
Why?
|
| Cesarean Section | 2 | 2017 | 1418 | 0.110 |
Why?
|
| Congenital Abnormalities | 1 | 2018 | 704 | 0.110 |
Why?
|
| Uveal Neoplasms | 1 | 2016 | 343 | 0.110 |
Why?
|
| Desmin | 2 | 2004 | 99 | 0.110 |
Why?
|
| Microsatellite Repeats | 2 | 2006 | 784 | 0.110 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 75 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2022 | 2795 | 0.110 |
Why?
|
| Lymphatic System | 1 | 2015 | 250 | 0.110 |
Why?
|
| Mixed Tumor, Malignant | 1 | 2012 | 16 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2021 | 3733 | 0.100 |
Why?
|
| Uterine Cervical Dysplasia | 2 | 2014 | 391 | 0.100 |
Why?
|
| Receptor, erbB-2 | 3 | 2021 | 2592 | 0.100 |
Why?
|
| Chloride Channels | 1 | 2013 | 221 | 0.100 |
Why?
|
| Mediator Complex | 1 | 2013 | 106 | 0.100 |
Why?
|
| Desmosomes | 2 | 2010 | 72 | 0.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2021 | 5752 | 0.100 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2013 | 750 | 0.100 |
Why?
|
| Cell Proliferation | 8 | 2020 | 10426 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 4 | 2014 | 9239 | 0.100 |
Why?
|
| Thoracic Neoplasms | 1 | 1994 | 267 | 0.100 |
Why?
|
| California | 1 | 2016 | 1435 | 0.100 |
Why?
|
| International Cooperation | 3 | 2017 | 1433 | 0.090 |
Why?
|
| Incidence | 3 | 2023 | 21513 | 0.090 |
Why?
|
| Torsion Abnormality | 1 | 2012 | 92 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 2 | 2010 | 5450 | 0.090 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2011 | 35 | 0.090 |
Why?
|
| Diagnostic Imaging | 3 | 2011 | 3530 | 0.090 |
Why?
|
| Survival Analysis | 8 | 2014 | 10086 | 0.090 |
Why?
|
| Base Sequence | 4 | 2019 | 12405 | 0.090 |
Why?
|
| Antigens, CD34 | 2 | 2004 | 656 | 0.090 |
Why?
|
| Japan | 1 | 2015 | 1411 | 0.090 |
Why?
|
| Pyrazoles | 1 | 2021 | 2031 | 0.090 |
Why?
|
| Skin Neoplasms | 2 | 2020 | 5836 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 5 | 2010 | 1695 | 0.090 |
Why?
|
| Liver Failure | 1 | 2012 | 252 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2011 | 285 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 1104 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2023 | 36547 | 0.090 |
Why?
|
| Disease Progression | 4 | 2019 | 13614 | 0.090 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 252 | 0.080 |
Why?
|
| Antigens, CD | 5 | 2016 | 4023 | 0.080 |
Why?
|
| Immunotherapy | 3 | 2019 | 4746 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2011 | 412 | 0.080 |
Why?
|
| Specimen Handling | 2 | 2015 | 704 | 0.080 |
Why?
|
| Carboplatin | 4 | 2006 | 787 | 0.080 |
Why?
|
| Testis | 2 | 2004 | 782 | 0.080 |
Why?
|
| Mucin-4 | 1 | 2009 | 33 | 0.080 |
Why?
|
| Mitochondria | 2 | 2023 | 3669 | 0.080 |
Why?
|
| Cytoplasm | 5 | 2011 | 1498 | 0.080 |
Why?
|
| Sequence Analysis, RNA | 3 | 2022 | 2036 | 0.080 |
Why?
|
| DNA Methylation | 5 | 2021 | 4424 | 0.080 |
Why?
|
| Cell Line, Tumor | 10 | 2016 | 17060 | 0.080 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2010 | 116 | 0.080 |
Why?
|
| Tamoxifen | 2 | 2008 | 964 | 0.080 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 2011 | 206 | 0.080 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2012 | 1777 | 0.080 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2013 | 904 | 0.080 |
Why?
|
| Pelvis | 2 | 2023 | 737 | 0.080 |
Why?
|
| Gene Expression Profiling | 7 | 2019 | 9525 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 655 | 0.080 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 1243 | 0.080 |
Why?
|
| Thrombosis | 2 | 2021 | 2955 | 0.080 |
Why?
|
| World Health Organization | 4 | 2019 | 1326 | 0.080 |
Why?
|
| Sensitivity and Specificity | 8 | 2017 | 14643 | 0.070 |
Why?
|
| Homeodomain Proteins | 3 | 2013 | 2430 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2012 | 915 | 0.070 |
Why?
|
| Chorionic Gonadotropin | 2 | 2004 | 457 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2013 | 1117 | 0.070 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 161 | 0.070 |
Why?
|
| Bartholin's Glands | 1 | 2007 | 5 | 0.070 |
Why?
|
| Urinary Bladder | 1 | 2014 | 1155 | 0.070 |
Why?
|
| Fibroblast Growth Factors | 1 | 2013 | 871 | 0.070 |
Why?
|
| Antineoplastic Agents | 4 | 2023 | 13631 | 0.070 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 619 | 0.070 |
Why?
|
| Cardiovascular System | 1 | 2015 | 838 | 0.070 |
Why?
|
| Intraoperative Period | 1 | 2008 | 510 | 0.070 |
Why?
|
| Mucins | 2 | 2022 | 568 | 0.070 |
Why?
|
| Gene Deletion | 2 | 2024 | 2667 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1926 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2007 | 247 | 0.070 |
Why?
|
| Radiography, Interventional | 1 | 2014 | 1128 | 0.070 |
Why?
|
| Keratin-19 | 1 | 2006 | 33 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2011 | 722 | 0.070 |
Why?
|
| Blotting, Western | 5 | 2015 | 5019 | 0.070 |
Why?
|
| Genetic Testing | 2 | 2018 | 3594 | 0.070 |
Why?
|
| Peritoneal Dialysis | 1 | 2008 | 161 | 0.070 |
Why?
|
| Hemorrhage | 2 | 2021 | 3466 | 0.070 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2016 | 647 | 0.070 |
Why?
|
| Clinical Protocols | 2 | 2010 | 1435 | 0.070 |
Why?
|
| Parity | 1 | 2010 | 931 | 0.070 |
Why?
|
| History, 21st Century | 1 | 2013 | 1572 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2007 | 310 | 0.070 |
Why?
|
| Lysosomes | 1 | 2012 | 932 | 0.070 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 1060 | 0.070 |
Why?
|
| Gene Silencing | 2 | 2015 | 1504 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2014 | 20690 | 0.070 |
Why?
|
| Pyrazines | 1 | 2012 | 1204 | 0.070 |
Why?
|
| Health Planning Guidelines | 1 | 2007 | 151 | 0.070 |
Why?
|
| Immunoconjugates | 1 | 2014 | 976 | 0.060 |
Why?
|
| Genes, p53 | 2 | 2024 | 711 | 0.060 |
Why?
|
| Hematoporphyrin Photoradiation | 1 | 2005 | 17 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2014 | 1519 | 0.060 |
Why?
|
| Multivariate Analysis | 4 | 2020 | 12059 | 0.060 |
Why?
|
| Infusions, Parenteral | 1 | 2006 | 395 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2007 | 417 | 0.060 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2006 | 80 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 1314 | 0.060 |
Why?
|
| Maternal Welfare | 1 | 2006 | 113 | 0.060 |
Why?
|
| United States | 8 | 2021 | 72909 | 0.060 |
Why?
|
| Prospective Studies | 8 | 2019 | 54807 | 0.060 |
Why?
|
| Gynecologic Surgical Procedures | 1 | 2008 | 287 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2022 | 9065 | 0.060 |
Why?
|
| Carcinoma, Ductal | 1 | 2005 | 97 | 0.060 |
Why?
|
| alpha-Fetoproteins | 2 | 2004 | 227 | 0.060 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2004 | 47 | 0.060 |
Why?
|
| Signal Transduction | 4 | 2013 | 23597 | 0.060 |
Why?
|
| Umbilical Cord | 1 | 2006 | 178 | 0.060 |
Why?
|
| New York | 1 | 2007 | 880 | 0.060 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2007 | 184 | 0.060 |
Why?
|
| Cystadenocarcinoma | 1 | 2004 | 54 | 0.060 |
Why?
|
| Calcium-Binding Proteins | 2 | 2016 | 1077 | 0.060 |
Why?
|
| Appendiceal Neoplasms | 1 | 2006 | 155 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2012 | 1181 | 0.060 |
Why?
|
| Cystadenoma | 1 | 2004 | 76 | 0.060 |
Why?
|
| Testicular Hormones | 1 | 2004 | 188 | 0.060 |
Why?
|
| Autophagy | 1 | 2012 | 1350 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2022 | 42510 | 0.060 |
Why?
|
| DNA Primers | 2 | 2011 | 2824 | 0.060 |
Why?
|
| Brenner Tumor | 1 | 2003 | 9 | 0.060 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2005 | 125 | 0.060 |
Why?
|
| Thrombophilia | 1 | 2007 | 308 | 0.060 |
Why?
|
| S100 Proteins | 1 | 2004 | 214 | 0.060 |
Why?
|
| Ferritins | 2 | 2017 | 600 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2014 | 3796 | 0.060 |
Why?
|
| Calcium | 2 | 2016 | 5769 | 0.060 |
Why?
|
| Peritoneal Diseases | 1 | 2024 | 76 | 0.050 |
Why?
|
| Mesonephros | 1 | 2003 | 42 | 0.050 |
Why?
|
| Placenta Diseases | 1 | 2006 | 199 | 0.050 |
Why?
|
| Recurrence | 5 | 2024 | 8492 | 0.050 |
Why?
|
| Intermediate Filament Proteins | 1 | 2004 | 261 | 0.050 |
Why?
|
| Porphyrins | 1 | 2005 | 351 | 0.050 |
Why?
|
| Risk Factors | 8 | 2024 | 74850 | 0.050 |
Why?
|
| Serine Endopeptidases | 1 | 2008 | 1024 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2018 | 26380 | 0.050 |
Why?
|
| Italy | 3 | 2017 | 851 | 0.050 |
Why?
|
| Up-Regulation | 4 | 2013 | 4130 | 0.050 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2007 | 701 | 0.050 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2004 | 266 | 0.050 |
Why?
|
| Hyperplasia | 3 | 2022 | 1142 | 0.050 |
Why?
|
| BRCA1 Protein | 1 | 2009 | 1155 | 0.050 |
Why?
|
| Adipogenesis | 1 | 2005 | 370 | 0.050 |
Why?
|
| Genes, ras | 1 | 2005 | 656 | 0.050 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2022 | 41 | 0.050 |
Why?
|
| Asia | 1 | 2024 | 630 | 0.050 |
Why?
|
| Kidney | 2 | 2021 | 7073 | 0.050 |
Why?
|
| Mice | 13 | 2023 | 81782 | 0.050 |
Why?
|
| Rete Testis | 1 | 2022 | 10 | 0.050 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2008 | 731 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2014 | 2206 | 0.050 |
Why?
|
| MicroRNAs | 3 | 2013 | 3788 | 0.050 |
Why?
|
| Antigens, Neoplasm | 2 | 2000 | 1995 | 0.050 |
Why?
|
| CA-125 Antigen | 1 | 2005 | 282 | 0.050 |
Why?
|
| Mesoderm | 1 | 2005 | 679 | 0.050 |
Why?
|
| Inflammation | 2 | 2021 | 10843 | 0.050 |
Why?
|
| Thrombomodulin | 1 | 2003 | 107 | 0.050 |
Why?
|
| Creatinine | 1 | 2008 | 1916 | 0.050 |
Why?
|
| Point Mutation | 3 | 2003 | 1590 | 0.050 |
Why?
|
| Sirolimus | 1 | 2009 | 1541 | 0.050 |
Why?
|
| Acute Disease | 2 | 2011 | 7236 | 0.050 |
Why?
|
| Radiography, Abdominal | 1 | 2005 | 543 | 0.050 |
Why?
|
| Genomics | 3 | 2024 | 5925 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2008 | 1763 | 0.050 |
Why?
|
| Down-Regulation | 3 | 2016 | 2925 | 0.050 |
Why?
|
| Mediastinum | 1 | 2003 | 271 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2013 | 1407 | 0.050 |
Why?
|
| Animals | 17 | 2023 | 168735 | 0.050 |
Why?
|
| Hernia, Ventral | 1 | 2005 | 220 | 0.050 |
Why?
|
| Glutathione Synthase | 1 | 2001 | 3 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2022 | 24275 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p19 | 1 | 2021 | 12 | 0.050 |
Why?
|
| Medical Records | 1 | 2007 | 1408 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 4 | 2018 | 5784 | 0.050 |
Why?
|
| Pelvic Exenteration | 1 | 2021 | 22 | 0.050 |
Why?
|
| Myxosarcoma | 1 | 2000 | 11 | 0.050 |
Why?
|
| Abdominal Pain | 2 | 2005 | 1069 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 2 | 2004 | 1609 | 0.040 |
Why?
|
| ras Proteins | 1 | 2006 | 1054 | 0.040 |
Why?
|
| Fetal Diseases | 1 | 2006 | 915 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2010 | 6321 | 0.040 |
Why?
|
| Anemia, Hemolytic, Congenital | 1 | 2001 | 71 | 0.040 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2006 | 587 | 0.040 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2021 | 76 | 0.040 |
Why?
|
| Ki-67 Antigen | 2 | 2013 | 628 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2004 | 615 | 0.040 |
Why?
|
| Spain | 3 | 2013 | 483 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2003 | 1984 | 0.040 |
Why?
|
| Mediastinal Neoplasms | 1 | 2003 | 403 | 0.040 |
Why?
|
| Condylomata Acuminata | 1 | 2000 | 79 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2020 | 8279 | 0.040 |
Why?
|
| CDC2 Protein Kinase | 1 | 2021 | 212 | 0.040 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2006 | 616 | 0.040 |
Why?
|
| Mucin-1 | 1 | 2004 | 535 | 0.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 1535 | 0.040 |
Why?
|
| Databases, Factual | 3 | 2020 | 8060 | 0.040 |
Why?
|
| RNA, Viral | 2 | 2018 | 2866 | 0.040 |
Why?
|
| Ovarian Follicle | 1 | 2021 | 244 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2007 | 1351 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2023 | 740 | 0.040 |
Why?
|
| Carcinoid Tumor | 1 | 2001 | 225 | 0.040 |
Why?
|
| Apyrase | 1 | 2002 | 376 | 0.040 |
Why?
|
| Portugal | 1 | 2019 | 91 | 0.040 |
Why?
|
| Pedigree | 1 | 2007 | 4535 | 0.040 |
Why?
|
| Sclerosis | 1 | 2020 | 211 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2009 | 2076 | 0.040 |
Why?
|
| Tubulin | 1 | 2003 | 693 | 0.040 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2021 | 228 | 0.040 |
Why?
|
| Actins | 2 | 2004 | 2057 | 0.040 |
Why?
|
| Hepatitis C | 1 | 2009 | 1596 | 0.040 |
Why?
|
| Canada | 2 | 2017 | 2120 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2021 | 2879 | 0.040 |
Why?
|
| RNA, Neoplasm | 2 | 2012 | 745 | 0.040 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2020 | 474 | 0.040 |
Why?
|
| Penile Neoplasms | 1 | 2000 | 158 | 0.040 |
Why?
|
| Trans-Activators | 2 | 2005 | 2848 | 0.040 |
Why?
|
| Hormones | 1 | 2022 | 865 | 0.040 |
Why?
|
| Taxoids | 1 | 2001 | 665 | 0.040 |
Why?
|
| Mice, Transgenic | 3 | 2023 | 9541 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 10727 | 0.040 |
Why?
|
| Sternum | 1 | 1999 | 177 | 0.040 |
Why?
|
| Algorithms | 1 | 2018 | 14064 | 0.040 |
Why?
|
| Shoulder | 1 | 2019 | 298 | 0.040 |
Why?
|
| Workflow | 1 | 2022 | 859 | 0.040 |
Why?
|
| Prostatic Neoplasms | 3 | 2006 | 11090 | 0.040 |
Why?
|
| Infant | 2 | 2018 | 36426 | 0.040 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1997 | 95 | 0.030 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2017 | 48 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 2008 | 2100 | 0.030 |
Why?
|
| Glycoproteins | 1 | 2004 | 2196 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2013 | 2008 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2005 | 5987 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2002 | 1130 | 0.030 |
Why?
|
| New York City | 1 | 2019 | 736 | 0.030 |
Why?
|
| Urethral Diseases | 1 | 1996 | 52 | 0.030 |
Why?
|
| Consensus | 2 | 2018 | 3202 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 2594 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2003 | 325 | 0.030 |
Why?
|
| gamma Catenin | 1 | 2016 | 45 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 4213 | 0.030 |
Why?
|
| alpha Catenin | 1 | 2016 | 37 | 0.030 |
Why?
|
| Gender Identity | 1 | 2022 | 766 | 0.030 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 1997 | 209 | 0.030 |
Why?
|
| Epigenomics | 1 | 2022 | 958 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2007 | 2857 | 0.030 |
Why?
|
| Vagina | 1 | 2022 | 849 | 0.030 |
Why?
|
| Desmoplakins | 1 | 2016 | 64 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2017 | 316 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2018 | 640 | 0.030 |
Why?
|
| Northern Ireland | 1 | 2015 | 37 | 0.030 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2016 | 148 | 0.030 |
Why?
|
| Cystectomy | 1 | 2000 | 603 | 0.030 |
Why?
|
| Venous Thromboembolism | 1 | 2009 | 1883 | 0.030 |
Why?
|
| Luteinization | 1 | 2015 | 10 | 0.030 |
Why?
|
| Palliative Care | 1 | 2011 | 3640 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 329 | 0.030 |
Why?
|
| Mice, SCID | 2 | 2013 | 2626 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2021 | 2676 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2020 | 698 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2012 | 18292 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2014 | 3608 | 0.030 |
Why?
|
| Peritoneum | 1 | 1996 | 226 | 0.030 |
Why?
|
| Microdissection | 1 | 2015 | 150 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2019 | 6202 | 0.030 |
Why?
|
| Integrases | 2 | 2009 | 520 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2008 | 3615 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 1998 | 354 | 0.030 |
Why?
|
| Hedgehog Proteins | 1 | 2020 | 772 | 0.030 |
Why?
|
| Ikaros Transcription Factor | 1 | 2016 | 230 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2001 | 1272 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2001 | 1635 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 22327 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 1374 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2020 | 4780 | 0.030 |
Why?
|
| Cohort Studies | 4 | 2021 | 41680 | 0.030 |
Why?
|
| Fertility | 1 | 2019 | 770 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2021 | 944 | 0.030 |
Why?
|
| Carcinoma, Medullary | 1 | 1995 | 115 | 0.030 |
Why?
|
| Massachusetts | 1 | 2007 | 8882 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1998 | 1072 | 0.030 |
Why?
|
| Poland | 1 | 2014 | 197 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 1995 | 283 | 0.030 |
Why?
|
| Kidney Transplantation | 1 | 2009 | 4277 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2013 | 2492 | 0.030 |
Why?
|
| Sweden | 1 | 2017 | 1381 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 22340 | 0.030 |
Why?
|
| Cystadenoma, Mucinous | 1 | 1993 | 62 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2008 | 6422 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2016 | 608 | 0.030 |
Why?
|
| Adipose Tissue | 2 | 2021 | 3314 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2015 | 266 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 3 | 2005 | 6101 | 0.030 |
Why?
|
| HIV Protease | 1 | 2013 | 99 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2016 | 608 | 0.030 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 3816 | 0.030 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 869 | 0.030 |
Why?
|
| Periodicals as Topic | 1 | 2024 | 1463 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2019 | 2108 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2000 | 1786 | 0.020 |
Why?
|
| Pharyngeal Neoplasms | 1 | 1992 | 113 | 0.020 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2012 | 45 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 2 | 2012 | 1621 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 3690 | 0.020 |
Why?
|
| Trophoblasts | 1 | 1993 | 223 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2018 | 1531 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2002 | 2916 | 0.020 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 3419 | 0.020 |
Why?
|
| Lactates | 1 | 2012 | 398 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2013 | 231 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2001 | 2394 | 0.020 |
Why?
|
| Molecular Biology | 1 | 2015 | 573 | 0.020 |
Why?
|
| Fluorescence | 1 | 2014 | 751 | 0.020 |
Why?
|
| Cisplatin | 2 | 2010 | 1654 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2011 | 310 | 0.020 |
Why?
|
| Phototherapy | 1 | 2014 | 369 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2022 | 2339 | 0.020 |
Why?
|
| International Normalized Ratio | 1 | 2012 | 382 | 0.020 |
Why?
|
| Bilirubin | 1 | 2012 | 439 | 0.020 |
Why?
|
| Ambulatory Care | 1 | 2001 | 2778 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2005 | 4959 | 0.020 |
Why?
|
| Cytoplasmic Structures | 1 | 2010 | 21 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 1999 | 1678 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 3940 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 8107 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2018 | 4851 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 249 | 0.020 |
Why?
|
| Histocytochemistry | 1 | 1991 | 695 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 26282 | 0.020 |
Why?
|
| Logistic Models | 2 | 2017 | 13273 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 2536 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 1999 | 1544 | 0.020 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2012 | 637 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 302 | 0.020 |
Why?
|
| Thyroid Neoplasms | 2 | 1995 | 2354 | 0.020 |
Why?
|
| Patient Selection | 1 | 2001 | 4248 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1991 | 280 | 0.020 |
Why?
|
| Luciferases | 1 | 2011 | 712 | 0.020 |
Why?
|
| Intermediate Filaments | 1 | 2010 | 171 | 0.020 |
Why?
|
| Microvessels | 1 | 2013 | 590 | 0.020 |
Why?
|
| Case-Control Studies | 4 | 2009 | 22228 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 3690 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2008 | 3542 | 0.020 |
Why?
|
| Registries | 2 | 2017 | 8346 | 0.020 |
Why?
|
| Cell Survival | 1 | 2018 | 5745 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2007 | 2390 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 752 | 0.020 |
Why?
|
| Contrast Media | 2 | 2012 | 5330 | 0.020 |
Why?
|
| Ultrafiltration | 1 | 2008 | 46 | 0.020 |
Why?
|
| Lentivirus | 1 | 2011 | 518 | 0.020 |
Why?
|
| Thyroid Gland | 1 | 1995 | 1168 | 0.020 |
Why?
|
| Comorbidity | 2 | 2016 | 10575 | 0.020 |
Why?
|
| China | 1 | 2014 | 2383 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2010 | 683 | 0.020 |
Why?
|
| Light | 1 | 2014 | 1364 | 0.020 |
Why?
|
| Sertoli-Leydig Cell Tumor | 2 | 1998 | 21 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 949 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 2829 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 1748 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 6491 | 0.020 |
Why?
|
| SEER Program | 1 | 2012 | 1443 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 7599 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2008 | 268 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 1729 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2008 | 405 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 1894 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2009 | 777 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 2004 | 5189 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2012 | 12768 | 0.020 |
Why?
|
| Stomach | 1 | 1991 | 702 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2011 | 1601 | 0.020 |
Why?
|
| Internet | 1 | 2019 | 3106 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 21069 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 2002 | 2232 | 0.020 |
Why?
|
| Plasmids | 1 | 2011 | 2267 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2012 | 2603 | 0.020 |
Why?
|
| Genotype | 2 | 2010 | 13026 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 2005 | 410 | 0.020 |
Why?
|
| Rats | 1 | 2021 | 23708 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2005 | 6958 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 3604 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 5364 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2009 | 1637 | 0.010 |
Why?
|
| Safety | 1 | 2009 | 1157 | 0.010 |
Why?
|
| Microsatellite Instability | 1 | 2008 | 726 | 0.010 |
Why?
|
| Papillomavirus Vaccines | 1 | 2010 | 495 | 0.010 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 2744 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 2455 | 0.010 |
Why?
|
| Endoscopy | 1 | 2014 | 1854 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2018 | 12417 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 3238 | 0.010 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1999 | 3682 | 0.010 |
Why?
|
| Biological Transport | 1 | 2008 | 2081 | 0.010 |
Why?
|
| Longitudinal Studies | 2 | 2011 | 14745 | 0.010 |
Why?
|
| Transfection | 1 | 2011 | 5738 | 0.010 |
Why?
|
| Mice, Inbred NOD | 1 | 2007 | 1837 | 0.010 |
Why?
|
| Histocytological Preparation Techniques | 1 | 2003 | 31 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2003 | 425 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2015 | 3079 | 0.010 |
Why?
|
| Swine | 1 | 2012 | 5986 | 0.010 |
Why?
|
| Bone Marrow Purging | 1 | 2002 | 108 | 0.010 |
Why?
|
| Thiotepa | 1 | 2001 | 66 | 0.010 |
Why?
|
| CHO Cells | 1 | 2004 | 1372 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2009 | 1343 | 0.010 |
Why?
|
| Cell Separation | 1 | 2007 | 1718 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 2002 | 119 | 0.010 |
Why?
|
| Life Tables | 1 | 2002 | 366 | 0.010 |
Why?
|
| Epithelium | 2 | 1996 | 1603 | 0.010 |
Why?
|
| Leukapheresis | 1 | 2002 | 150 | 0.010 |
Why?
|
| Mitoxantrone | 1 | 2001 | 148 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2005 | 1751 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2010 | 1725 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2009 | 1187 | 0.010 |
Why?
|
| Photosensitizing Agents | 1 | 2005 | 626 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 2412 | 0.010 |
Why?
|
| Malondialdehyde | 1 | 2001 | 113 | 0.010 |
Why?
|
| Trisomy | 1 | 2002 | 260 | 0.010 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2001 | 66 | 0.010 |
Why?
|
| ROC Curve | 1 | 2009 | 3612 | 0.010 |
Why?
|
| Age Factors | 3 | 2010 | 18382 | 0.010 |
Why?
|
| Proteomics | 1 | 2014 | 3906 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2000 | 65 | 0.010 |
Why?
|
| Linear Models | 1 | 2010 | 5873 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2009 | 1881 | 0.010 |
Why?
|
| Carcinoma, Verrucous | 1 | 2000 | 26 | 0.010 |
Why?
|
| DNA | 1 | 1994 | 7193 | 0.010 |
Why?
|
| Melphalan | 1 | 2001 | 425 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 2915 | 0.010 |
Why?
|
| DNA Damage | 1 | 2010 | 2462 | 0.010 |
Why?
|
| Chromogranins | 1 | 2000 | 159 | 0.010 |
Why?
|
| Vincristine | 1 | 2002 | 1037 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 2125 | 0.010 |
Why?
|
| Cell Line | 1 | 2013 | 15540 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 1322 | 0.010 |
Why?
|
| Mediastinitis | 1 | 1999 | 49 | 0.010 |
Why?
|
| Probability | 1 | 2004 | 2474 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2010 | 3431 | 0.010 |
Why?
|
| Back Pain | 1 | 2003 | 546 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2012 | 3360 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 2844 | 0.010 |
Why?
|
| X Chromosome | 1 | 2002 | 819 | 0.010 |
Why?
|
| Adipocytes | 1 | 2005 | 1195 | 0.010 |
Why?
|
| Epididymis | 1 | 2000 | 227 | 0.010 |
Why?
|
| Cytokines | 1 | 2013 | 7417 | 0.010 |
Why?
|
| Mucous Membrane | 1 | 2001 | 658 | 0.010 |
Why?
|
| Favism | 1 | 1997 | 3 | 0.010 |
Why?
|
| Leg | 1 | 2003 | 1088 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2001 | 614 | 0.010 |
Why?
|
| Africa, Northern | 1 | 1997 | 86 | 0.010 |
Why?
|
| Prednisone | 1 | 2002 | 1566 | 0.010 |
Why?
|
| Exons | 1 | 2003 | 2393 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 2002 | 1009 | 0.010 |
Why?
|
| Neutropenia | 1 | 2001 | 894 | 0.010 |
Why?
|
| Debridement | 1 | 1999 | 494 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 2001 | 865 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2000 | 1616 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2007 | 2895 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5333 | 0.010 |
Why?
|
| Nucleolus Organizer Region | 1 | 1995 | 25 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2002 | 2226 | 0.010 |
Why?
|
| Silver Staining | 1 | 1995 | 62 | 0.010 |
Why?
|
| Microvilli | 1 | 1995 | 234 | 0.010 |
Why?
|
| Luteal Cells | 1 | 1994 | 19 | 0.010 |
Why?
|
| Mass Screening | 1 | 2010 | 5449 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2004 | 2463 | 0.010 |
Why?
|
| Infection Control | 1 | 2001 | 984 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2009 | 14450 | 0.010 |
Why?
|
| Fever | 1 | 2001 | 1607 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 1995 | 223 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 1997 | 735 | 0.010 |
Why?
|
| Flow Cytometry | 2 | 1994 | 5880 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2003 | 1878 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 17596 | 0.010 |
Why?
|
| Plasma Cells | 1 | 1996 | 596 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 9351 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1995 | 2543 | 0.010 |
Why?
|
| Oropharynx | 1 | 1992 | 139 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2001 | 6306 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1998 | 1491 | 0.010 |
Why?
|
| Risk | 1 | 2001 | 9599 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 1978 | 1412 | 0.000 |
Why?
|
| Peptides | 1 | 2000 | 4331 | 0.000 |
Why?
|
| Pain | 1 | 2003 | 5077 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2004 | 7847 | 0.000 |
Why?
|
| Biopsy, Needle | 1 | 1992 | 1613 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 4249 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 15878 | 0.000 |
Why?
|
| Postoperative Care | 1 | 1992 | 1475 | 0.000 |
Why?
|
| Proteins | 1 | 2000 | 5994 | 0.000 |
Why?
|
| Radiotherapy Dosage | 1 | 1992 | 2863 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 7473 | 0.000 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1994 | 8924 | 0.000 |
Why?
|
| Marriage | 1 | 1978 | 351 | 0.000 |
Why?
|
| Educational Status | 1 | 1978 | 2510 | 0.000 |
Why?
|
| Family | 1 | 1978 | 3208 | 0.000 |
Why?
|
| Socioeconomic Factors | 1 | 1978 | 7842 | 0.000 |
Why?
|
| Sex Factors | 1 | 1978 | 10611 | 0.000 |
Why?
|
| Mental Disorders | 1 | 1978 | 6870 | 0.000 |
Why?
|